TY - JOUR
T1 - Development and Validation of the 5-SENSE Score to Predict Focality of the Seizure-Onset Zone as Assessed by Stereoelectroencephalography
AU - Astner-Rohracher, Alexandra
AU - Zimmermann, Georg
AU - Avigdor, Tamir
AU - Abdallah, Chifaou
AU - Barot, Nirav
AU - Brázdil, Milan
AU - Doležalová, Irena
AU - Gotman, Jean
AU - Hall, Jeffery Alan
AU - Ikeda, Kirsten
AU - Kahane, Philippe
AU - Kalss, Gudrun
AU - Kokkinos, Vasileios
AU - Leitinger, Markus
AU - Mindruta, Ioana
AU - Minotti, Lorella
AU - Mizera, Mary Margaret
AU - Oane, Irina
AU - Richardson, Mark
AU - Schuele, Stephan U.
AU - Trinka, Eugen
AU - Urban, Alexandra
AU - Whatley, Benjamin
AU - Dubeau, François
AU - Frauscher, Birgit
N1 - Funding Information:
Astner-Rohracher reported personal fees from Eisai (travel support and speaker honoraria) outside the submitted work. Dr Zimmermann reported grants from Federal State of Salzburg during the conduct of the study. Mr Avigdor is supported by the Canadian Open Neuroscience Platform. Dr Abdallah reported PhD studentship from Savoy Foundation. Dr Gotman reported grants from Canadian Institutes of Health Research during the conduct of the study. Dr Leitinger reported a travel grant from UCB Pharma and a speaker honorarium from Eisai outside of the submitted work. Dr Schuele reported personal fees from SK Life Science, Greenwhich Biosciences, Neurelis, Sunovion, Eisai, Epilog, and Monteris and grants from National Institute on Deafness and Other Communication Disorders and National Institute of Neurologic Disorders and Stroke outside the submitted work. Dr Trinka reported personal fees from UCB, Eisai, Marinus Pharmaceuticals, LivaNova, NewBridge, Hikma, EVER Pharma, Argenix, GL Pharma, GlaxoSmithKline, Biogen, Actavis, GW
Funding Information:
Pharmaceuticals, Sanofi and Novartis outside the submitted work; grants from Bial, Boehringer Ingelheim, GW Pharmaceuticals, Eisai, and Bayer outside the submitted work; and his institution has received grants from Biogen, UCB Pharma, Eisai, Red Bull, Merck, Bayer, the European Union, FWF Osterreichischer Fond zur Wissenschaftsforderung, undesministerium für Wissenschaft und Forschung, and Jubilaumsfond der Österreichischen Nationalbank outside the submitted work. Dr Urban reported personal fees from NeuroPace. Dr Frauscher reported a salary award from Fonds de Recherche du Québec and grants from Montreal Neurological Institute during the conduct of the study; personal fees from Eisai and UCB outside the submitted work; grants from Eisai outside the submitted work; and her research program is supported by the Canadian Institutes of Health Research, the Canadian Foundation for Innovation, the Natural Sciences and Engineering Research Council of Canada, the Savoy Epilepsy Foundation, the Hewitt Foundation, and start-up funding of the Montreal Neurological Institute. No other disclosures were reported.
Funding Information:
Funding/Support: This project was supported by start-up funding of the Montreal Neurological Institute and Hospital to Dr Frauscher. Dr Astner-Rohracher received a research grant from the Österreichische Gesellschaft für Epileptologie, the Austrian chapter of the International League Against Epilepsy. Dr Zimmermann gratefully acknowledges the support from Salzburg (grants 20204-WISS/225/197-2019 and 20102-F1901166-KZP). Dr Frauscher is supported by a salary award by Fonds de Recherche du Québec–Santé 2021-2025.
Publisher Copyright:
© 2022 American Medical Association. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Importance: Stereoelectroencephalography (SEEG) has become the criterion standard in case of inconclusive noninvasive presurgical epilepsy workup. However, up to 40% of patients are subsequently not offered surgery because the seizure-onset zone is less focal than expected or cannot be identified. Objective: To predict focality of the seizure-onset zone in SEEG, the 5-point 5-SENSE score was developed and validated. Design, Setting, and Participants: This was a monocentric cohort study for score development followed by multicenter validation with patient selection intervals between February 2002 to October 2018 and May 2002 to December 2019. The minimum follow-up period was 1 year. Patients with drug-resistant epilepsy undergoing SEEG at the Montreal Neurological Institute were analyzed to identify a focal seizure-onset zone. Selection criteria were 2 or more seizures in electroencephalography and availability of complete neuropsychological and neuroimaging data sets. For validation, patients from 9 epilepsy centers meeting these criteria were included. Analysis took place between May and July 2021. Main Outcomes and Measures: Based on SEEG, patients were grouped as focal and nonfocal seizure-onset zone. Demographic, clinical, electroencephalography, neuroimaging, and neuropsychology data were analyzed, and a multiple logistic regression model for developing a score to predict SEEG focality was created and validated in an independent sample. Results: A total of 128 patients (57 women [44.5%]; median [range] age, 31 [13-58] years) were analyzed for score development and 207 patients (97 women [46.9%]; median [range] age, 32 [16-70] years) were analyzed for validation. The score comprised the following 5 predictive variables: focal lesion on structural magnetic resonance imaging, absence of bilateral independent spikes in scalp electroencephalography, localizing neuropsychological deficit, strongly localizing semiology, and regional ictal scalp electroencephalography onset. The 5-SENSE score had an optimal mean (SD) probability cutoff for identifying a focal seizure-onset zone of 37.6 (3.5). Area under the curve, specificity, and sensitivity were 0.83, 76.3% (95% CI, 66.7-85.8), and 83.3% (95% CI, 72.30-94.1), respectively. Validation showed 76.0% (95% CI, 67.5-84.0) specificity and 52.3% (95% CI, 43.0-61.5) sensitivity. Conclusions and Relevance: High specificity in score development and validation confirms that the 5-SENSE score predicts patients where SEEG is unlikely to identify a focal seizure-onset zone. It is a simple and useful tool for assisting clinicians to reduce unnecessary invasive diagnostic burden on patients and overutilization of limited health care resources..
AB - Importance: Stereoelectroencephalography (SEEG) has become the criterion standard in case of inconclusive noninvasive presurgical epilepsy workup. However, up to 40% of patients are subsequently not offered surgery because the seizure-onset zone is less focal than expected or cannot be identified. Objective: To predict focality of the seizure-onset zone in SEEG, the 5-point 5-SENSE score was developed and validated. Design, Setting, and Participants: This was a monocentric cohort study for score development followed by multicenter validation with patient selection intervals between February 2002 to October 2018 and May 2002 to December 2019. The minimum follow-up period was 1 year. Patients with drug-resistant epilepsy undergoing SEEG at the Montreal Neurological Institute were analyzed to identify a focal seizure-onset zone. Selection criteria were 2 or more seizures in electroencephalography and availability of complete neuropsychological and neuroimaging data sets. For validation, patients from 9 epilepsy centers meeting these criteria were included. Analysis took place between May and July 2021. Main Outcomes and Measures: Based on SEEG, patients were grouped as focal and nonfocal seizure-onset zone. Demographic, clinical, electroencephalography, neuroimaging, and neuropsychology data were analyzed, and a multiple logistic regression model for developing a score to predict SEEG focality was created and validated in an independent sample. Results: A total of 128 patients (57 women [44.5%]; median [range] age, 31 [13-58] years) were analyzed for score development and 207 patients (97 women [46.9%]; median [range] age, 32 [16-70] years) were analyzed for validation. The score comprised the following 5 predictive variables: focal lesion on structural magnetic resonance imaging, absence of bilateral independent spikes in scalp electroencephalography, localizing neuropsychological deficit, strongly localizing semiology, and regional ictal scalp electroencephalography onset. The 5-SENSE score had an optimal mean (SD) probability cutoff for identifying a focal seizure-onset zone of 37.6 (3.5). Area under the curve, specificity, and sensitivity were 0.83, 76.3% (95% CI, 66.7-85.8), and 83.3% (95% CI, 72.30-94.1), respectively. Validation showed 76.0% (95% CI, 67.5-84.0) specificity and 52.3% (95% CI, 43.0-61.5) sensitivity. Conclusions and Relevance: High specificity in score development and validation confirms that the 5-SENSE score predicts patients where SEEG is unlikely to identify a focal seizure-onset zone. It is a simple and useful tool for assisting clinicians to reduce unnecessary invasive diagnostic burden on patients and overutilization of limited health care resources..
UR - http://www.scopus.com/inward/record.url?scp=85120754390&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120754390&partnerID=8YFLogxK
U2 - 10.1001/jamaneurol.2021.4405
DO - 10.1001/jamaneurol.2021.4405
M3 - Article
C2 - 34870697
AN - SCOPUS:85120754390
VL - 79
SP - 70
EP - 79
JO - JAMA Neurology
JF - JAMA Neurology
SN - 2168-6149
IS - 1
ER -